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The effect of renal a2-andrenoceptor stimulation on prostaglandin E2
(POE2) induced cAMP formation. Previous studies in our laboratory
demonstrated that a2-adrenoceptor activation reversed arachidonic
acid induced diuresis in the rat. However, the site of action was not
elucidated. Since prostaglandin E2 is the predominant prostaglandin
metabolite of arachidonic acid, we studied the effect of renal a2-
adrenoceptor stimulation on prostaglandin E2 (POE2) induced cAMP
formation. The study was done in intact single nephron segments and
glomeruli. All incubations were done in the presence of l-methyl-3-
isobutyixanthine (phosphodiesterase inhibitor) and propranolol at 37°C
for two minutes. POE2 increased cellular cAMP levels in the thin
descending limb of Henle (tDL), cortical collecting tubule (CCT) and
glomerulus. Alpha2-adrenoceptors were activated with varying concen-
trations of epinephrine (E). In the tDL, a2-adrenoceptor activation with
E (5 x 106M to 5 x l05M) suppressed (p < 0.05) POE2 stimulated
cAMP production by 35%. This suppression by E was inhibited by 5 x
l06M yohimbine but not by 5 x l06M prazosin confirming a2-
adrenoceptor mediation of the effects of E. Conversely, in the CCT and
glomerulus, E had no effect on PGE2-stimulated increases in cellular
cAMP levels. Thus, the capacity of a2-adrenoceptors to inhibit POE2-
stimulated adenylate cyclase is anatomic site-specific. This effect of
a2-adrenoceptors on cAMP in the tDL may explain, at least in part, the
effect of a2-adrenoceptors on arachidonic acid induced diuresis in the
rat.
Recently, we reported that a2-adrenoceptor stimulation at-
tenuated the diuresis induced by arachidonic acid infusion in
the isolated perfused rat kidney [1]. However, the intra-renal
site(s) of action was not determined. Plasma membrane a-
adrenoceptors have been pharmacologically classified into a1—
and ar-subtypes [2, 3]. Renal a1— and a2—adrenoceptors have
been identified in whole kidney membranes with an impressive
numerical dominance of a2-adrenoceptors [4]. a2-adrenoceptor
stimulation has attenuated the hormonal stimulation of adenyl-
ate cyclase activity in many tissues [5] including specific
nephron segments [6, 7] and the glomerulus [8]. Prostaglandin
E2 (PGE2), the major renal active metabolite of arachidonic
acid, has been reported to stimulate adenylate cyclase in the
glomerulus [9], thin descending limb of Henle (tDL) and col-
lecting tubule (CT) [10, 11]. However, there is no report about
the interaction of of PGE2— and a2-adrenoceptor—stimulation on
the adenylate cyclase in the specific nephron segments. Thus,
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we investigated the effect of a2-adrenoceptor stimulation on the
PGE2 stimulated adenylate cyclase in these specific nephron
segments.
In the present study, the intact cell preparation was used. In
this preparation, PGE2 stimulated cAMP formation has been
shown [11]. As well, the inhibitory effect of a2-adrenoceptor
stimulation has also been documented in this preparation [6, 7].
Thus, we employed this system to examine the effect of
a-adrenoceptor stimulation on PGE2 induced cellular cAMP
formation. The specific segments studied were the glomerulus,
tDL and cortical collecting tubule (CCT). Specific a1- (prazosin)
and a2- (yohimbine) adrenoceptor antagonists were used to
confirm the specific a-adrenoceptor subtype mediating these
inhibitory effects.
Methods
Preparation of isolated single nephron segments and
glomeruli
Male Sprague-Dawley rats (Harlan, Houston, Texas, USA;
250 to 350g) were anesthetized by i.p. injection of pentobarbital
40 mg/kg. The right renal and superior mesenteric arteries were
ligated and a PE-50 polyethylene catheter was inserted in the
abdominal aorta below the left renal artery. Immediately before
washing and perfusion of the left kidney, the aorta was clamped
above the left renal artery. The left kidney was washed out by
a slow injection of 5 ml chilled Krebs-Ringer bicarbonate (KRB)
buffer (pH 7.4) equilibrated with 95% 02 and 5% CO2. This
buffer contained (in mM): NaC1, 118; KC1, 4.8; NaHCO3, 24;
KH2PO4, 1.2; MgSO4, 1.2; glucose, 11.0; NaEDTA, 0.026; and
CaC12, 2.5. This wash was followed by a rapid infusion over five
sec of 10 ml ice-cold buffer containing 10 mg bovine serum
albumin (BSA) and 10 mg collagenase (KRB-BSA-collagenase
buffer).
The left kidney was removed and slices of kidney tissue
dissected on the cortico-medullary plane. These slices were
usually incubated at 30°C for 30 mm in KRB-BSA-collagenase
buffer exposed to 95% 02 and 5% CO2. Following incubation,
kidney slices were rinsed three times with 80 ml of ice-cold
modified Hank's solution (pH 7.4) containing (in mM): NaCI,
137; KC1, 5.4; NaHCO3, 4.2; Na2HPO4, 0.34; KH2PO4, 0.44;
MgSO4, 1.0 and 0.1% glucose.
The microdissection of tubule segments or glomeruli was
performed manually under a stereomicroscope in an ice-cold
modified Hanks'-Hepes solution, pH 7.4, containing (in mM):
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NaCI, 137; KC1, 5.4, Na2HPO4, 0.34; KH2PO4, 0,44; CaC12, 1.0;
MgCI,, 0.5; MgSO4, 0.5; 1-methyl-3-isobutylxanthine (MIX),
1.2; Hepes, 20; glucose, 5.5 and 0.05% BSA. Identification of
nephron segments was based on criteria described by Morel
[12] and by us [7]. In brief, the tDL located in the inner stripe of
the outer medulla or inner medulla was isolated with the pars
recta attached. The CCT was located in the cortex with a
granular, light and straight appearance. Isolated glomeruli were
without capsules and arterioles, and the structure was well
preserved.
Tubule length was measured with the reticle attached to the
stereomicroscope. One to four single nephron segments (total
length 1.3 mm), or two glomeruli were transferred in 20 itl of
modified Hanks'—Hepes solution to a siliconized glass culture
tube for enzyme assay.
Incubation and assay of cAMP in intact tubule segments
and glomeruli
Incubation and assay of cellular cAMP in tubule segments
and glomeruli was similar to that of previous reports described
by us [7, 8J and by others [11, 13].
After 5 mm of preincubation at 37°C, 20 tl of modified
Hanks '—Hepes solution containing appropriate test hormone(s),
hormone antagonist(s), propranolol (5 X l06M), or vehicle was
added to the incubation medium, and the incubation continued
for an additional 2 mm at 37°C. The reaction was terminated by
the addition of 50 1d 10% trichloroacetic acid, and the mixture
vortexed and extracted three times with 0.8 ml of water-
saturated ether. The resultant aqueous phase was dried at 40 to
45°C and the tubes kept at —20° until assay of the cAMP.
Immediately prior to the assay, 100 ,i.tl of 50 m sodium
acetate buffer (pH 6.2) was added to each vial, mixed and
acetylated to enhance the sensitivity for radioimmunoassay.
cAMP was determined by a radioimmunoassay kit, purchased
from New England Nuclear (Boston, Massachusetts, USA).
In preliminary experiments, recovery of [3H]cAMP added
together with TCA was 95 to 101%. Because of this essentially
complete recovery and because of the potential for interference
of added tracer, we did not include [3H]cAMP as a recovery
marker in our experiments. This is consonant with previous
experience [7, 11, 13]. A linear relationship was observed
between the tubular fragment length of CCT (from 1 to 6 mm)
[71 or tDL (Fig. lb) or number of glomeruli (from one to six) [81
and cAMP levels, The correlation coefficients were R 0.93,
0.97, and 0.99 respectively, all having P < 0.001. Statistical
analyses were performed with an analysis of variance. Homo-
geneity of the variances of the groups studied was established
with Bartlett's test [14]. The level of significance between
groups was determined with Newman-Keuls Multiple Compar-
ison [14]. As well, Student's t test was used.
Materials
The following compounds were ohtained from Sigma Chem-
ical Company (St. Louis, Missouri, USA): l-methyl-3-
isobutylxanthine (MIX), collagenase (type I), (—)-epinephrine
bitartrate, dl-propranolol HCI, yohimbine HC1 and N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid (Hepes). Bo-
vine serum albumin (CRG-7) was purchased from Armour
Pharmaceutical Company (Chicago, Illlinois, USA), and
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Fig. 1. (a) Time course of cAMP accumulation in the tDL. In this
experiment, 1.3 mm of the tDL was incubated with l04M PGE2 for
varying lengths of time. (b) Relationship between cAMP levels and the
tubule length of the tDL. In this experiment, varying lengths of tDL
were incubated for two minutes with or without ('5 105M POE2. Each
point represents the mean 5E of three incubations. The correlation
coefficient was R = 0.97, P < 0.001 for the incubation with POE2.
Hanks' balanced salt solution was from GIBCO (Chargin Falls,
Ohio, USA). POE2 was supplied by the Upjohn Company
(Kalamazoo, Michigan, USA), and prazosin by Pfizer (New
York, New York).
Results
Characteristics of cAMP accumulation in the tDL
The time-course of PGE2-induced cellular cAMP production
was studied (Fig. lA). The cAMP levels increased as a function
of time up to approximately two to three minutes. Thus, we
chose two minutes of incubation for all subsequent experi-
ments. This incubation time has been previously reported in our
laboratory [7, 81 and others [11, 131 in studies with renal tubules
and glomeruli.
A linear relationship was observed between the length of
tubules and cAMP formed during the two minutes of incubation
with POE2 (Fig. lB). A dose-response relationship between
POE2 and cAMP levels in the tDL was studied (Fig. 2).
Half-maximum stimulation occurred at 3 x l07M POE2 and
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Fig. 2. Dose-dependent increase in cAMP levels of the tDL in response
to PGE2. Segments of tDL from a single rat kidney were incubated with
varying concentrations of PGE2. Each point is the mean SE of
quadruplicate incubations. The average of half-maximum stimulation
by PGE2 determined from three separate experiments (rats) was 3 x
107M.
the previous report [11].
cx2-Adrenoceptor activation in the PGE2 stimulated cAMP
levels in the tDL
a2-Adrenoceptor activation with (—)epinephrine (E) inhibited
PGE2 dependent increases in cAMP levels. This occurred in a
dose dependent manner (Fig. 3), with a maximum of 35%
inhibition (Figs. 3, 5). This E-induced inhibition of cAMP was
antagonized by the specific a2-adrenoceptor antagonist
yohimbine (Figs. 4, 5). In the absence of E, this concentration
of yohimbine alone had no significant effect on PGE2 stimulated
cAMP levels (40.0 5.7 vs. 47.3 5.5 fmole/mm; N = 4; PGE2
vs. PGE2 + yohimbine). In contrast, the specific a1-adrenocep-
tor antagonist prazosin at a concentration of 5 x l06M had no
effect on this E-induced inhibition of cAMP formation (Fig. 5).
Finally, E (5 X l06M) alone had no inhibitory effect on basal
cAMP formation (5.3 1.4 vs. 7.2 2.8 fmole/mm; N = 4;
control vs. E).
cs2-Adrenoceptor activation in the PGE2 stimulated cAMP
levels in the glomerulus and in the CCT
In preliminary studies, the dose response curve between
glomerular cAMP levels and PGE2 showed near maximum
stimulation at 10—6 to 104M, as previously reported [8]. Thus,
we used this dose range of PGE2 in the present study. a2-
Adrenoceptor activation with E, however, failed to inhibit
cAMP generation induced by PGE2 in the glomerulus (Fig. 6).
As well, E had no inhibitory effect on basal cAMP formation
[8].
Epinephrine, —logiM]
Fig. 3. Effect of increasing E concentrations on the PGE2-stimulated
increase in cAMP levels in tDL. Isolated tubules were incubated with
105M PGE2, 5 x 106M di-propranolol and varying concentrations of
E. Each data point is the mean SE of three separate experiments
(rats).
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Fig. 4. Effect of yohimbine on epinephrine (E)-induced suppression of
cAMP levels in tDL. Isolated tubules were incubated with l05M PGE2,
5 x l06ri dl-propranolol, 5 x 106ri E and the varying concentrations
of yohimbine. Each data point represents the mean SE of quadrupli-
cate incubations in tubules taken from a single rat. The values with
PGE2 and propranolol (without E) were 45.6 9.2 fmole/mm. The
concentrations of yohimbine which half-maximally antagonized the
suppression of E were 3 x 107M (values determined from the average
Ki of three separate experiments).
60
50
40
30
E
E
5)
0
0
C.,
0 _uuuuIuo1I /I I0 '10 8 I6 4 I I
8 6
J
4
near maximum stimulation at 105M. The values were similar to 75 i—
0
_—//10 I6 J4
In the CCT, the significant increase of cAMP was observed
only at a very high concentration of PGE2 (2.7 0.9 vs. 9.1 ±
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Fig. S. Effect of cx2-adrenoceptor stimulation on POE2 stimulated cAMPlevels in the tDL. All tDL were incubated with 5 x l06M dl-
propranolol. Final concentration of the reagents are as follows: POE2,
1O5M; E, 5 x 106M; Y, 5 )< 106M; P, 5 X l0M, Values shown for
each experiment are the average (cAMP fmole/mm) of three to five
incubations. Each experiment was done in nephron segments dissected
from the same rat. Results represent the mean SE of five to eight
experiments (rats), p < 0,05,
3.1 fmole/mm; control vs 104M POE2, N — 5; P <0.05). This
is consistent with the previous reports [11]. Thus, we used
104M POE2 as a stimulant, However, E had no effect on POE2
stimulated cAMP levels (data not shown).
Discussion
Results of this study demonstrated for the first time that, in
the rat kidney, activation of a2-adrenoceptors inhibited POEr
dependent cAMP formation in the tDL. As well, this study
confirmed the results of a recent report that POE2 is capable of
effectively raising cellular cAMP in the tDL and CCT [11].
However, we were unable to produce a2-adrenoceptor medi-
ated inhibition of cAMP formation following stimulation by
POE2 in the glomerulus and in the CCT.
We have recently found [1] that in the isolated perfused
kidney, a2-adrenoceptor stimulation antagonizes the effect of
endogenous prostaglandins (POs) (the formation of which was
induced by arachidonic acid) on sodium and water excretion.
Adenosine P-site activation (SQ22, 536) also antagonized this
effect. Therefore, we concluded that this antagonistic effect was
through inhibition of adenylate cyclase. As well, absence of
hemodynamic changes suggested that the effects of a2-adreno-
ceptor stimulation occurred at the tubular level [1]. The present
study further suggested that the tDL could be one of the
possible sites of this antagonistic effect of a2-adrenoceptor
stimulation on POs-induced change in sodium and water excre-
tion.
Recent studies from our laboratory [7, 8] and others [6] have
demonstrated the inhibitory role of aradrenoceptor stimulation
on hormone activated adenylate cyclase in specific nephron
segments and in the glomerulus. In other studies, POE2 was
shown to stimulate adenylate cyclase activity in the tDL, CCT
and MCT in a broken cell system [10], in the tDL and CCT in an
intact cell system [11] and in the glomerulus [9]. Thus, the tDL,
CCT and the glomerulus were used to study the effect of
a2-adrenoceptor stimulation on POE2-stimulated adenylate cy-
clase. An intact cell system was used since the inhibitory effects
of a2-adrenoceptor stimulation on adenylate cyclase have been
demonstrated in this system [6, 7], whereas this linkage appears
to be disrupted in broken cell preparations [6, 7, 16].
Our results show that epinephrine inhibited cAMP formation
following stimulation by POE2 only in the tDL. Yohimbine, a
selective cx2-adrenoceptor blocker, reversed this inhibition by
E. Prazosin, a selective a1-adrenoceptor blocker, failed to
affect the inhibition. These results were consistent with the
postulate that this epinephrine-induced inhibitory effect on
cAMP formation in the tDL was due to a2-adrenoceptor stim-
ulation.
It is difficult to clearly link the biochemical results of this
study with a2-adrenoceptor inhibition of arachidonic acid
diuresis in the perfused rat kidney. Prostaglandins have signif-
icant effects on renal regulation of solute and water excretion
[17, 18] possibly through activation or inhibition of adenylate
cyclase [13, 19, 20]. Their direct effects on salt and water
transport have been demonstrated in collecting tubules and
thick ascending limb of Henle [18]. However, such effects in the
tDL and a role in the counter current system [21] have not been
demonstrated.
In vivo, a2-adrenoceptors may be activated by norepineph-
rine released from sympathetic nerve endings which have been
found widely distributed throughout the kidney [24]. However,
renal tubular a2-adrenoceptors in the rat have been proposed to
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Fig. 6. Effect of POE2 and POE2 plus epinephrine on cAMP levels in the
glomerulus. Isolated glomeruli were incubated in the presence of lO4M
or 105M POE2 and 5 x l06M dI-propranolol, with or without epineph-
rine. Results represent the mean SE of five to eight experiments (rats).
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be extrajunctional in location [25]. This was based on evidence
that catecholamine infusion, but not renal nerve stimulation,
induced an a2-adrenoceptor mediated effect. Thus, a2-
adrenoceptors may be activated primarily by circulating cate-
cholamines. For this reason, in the present study epinephrine
was selected to activate a2-adrenoceptors even though more
specific a2-adrenoceptor agonists were available.
The reason for the inability to demonstrate a2-adrenoceptor
suppression of the cAMP formation stimulated by PGE2 in the
CCT and the glomerulus was unclear. Recent studies have
demonstrated that a2-adrenoceptor stimulation can inhibit
cAMP formation stimulated by arginine vasopressin (AVP) in
the CCT [6] and by parathyroid hormone in the glomerulus [8].
As well, radioligand binding studies in the glomerulus [28] and
physiological studies in the CCT [29] have suggested the
existence of a2-adrenoceptors in these segments. However,
different cell types exist in the CCT and in the glomerulus. If
a2-adrenoceptors mainly exist on the cell which responds to
AVP in the CCT and to PTH in the glomerulus, a2-adrenoceptor
stimulation would not be expected to inhibit PGE2-stimulated
adenylate cyclase in these segments. Actually, in CCT, a2-
adrenoceptors can inhibit cAMP formation stimulated only by
AVP but not by glucagon, calcitonin and isoproterenol [6]. As
well, it was suggested that PTH and PGE2 are not linked to the
same pooi of adenylate cyclase in the glomerulus [30] and thus,
there may be a basis for hormone selectivity to be regulated by
a2-adrenoceptor activation.
In conclusion, the present study has demonstrated for the
first time that a2-adrenoceptors have a potent inhibitory effect
on cAMP formation stimulated by PGE2 in the tDL of the rat.
Conceivably, this site contributes to the a2-adrenoceptor rever-
sal of arachidonic acid-induced diuresis in the kidney.
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